+Compare
MDNA
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
20.64M

MDNA Medicenna Therapeutics Corp Forecast, Technical & Fundamental Analysis

a clinical stage immuno-oncology company which engages in development and commercialization of selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Cytokines for the treatment of cancers

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for MDNA with price predictions
08:00 PM EDT Sep 25, 2023

MDNA sees its Stochastic Oscillator ascending out of oversold territory

On September 21, 2023, the Stochastic Oscillator for MDNA moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 68 instances where the indicator left the oversold zone. In of the 68 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MDNA's RSI Indicator exited the oversold zone, of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for MDNA just turned positive on September 21, 2023. Looking at past instances where MDNA's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MDNA advanced for three days, in of 190 cases, the price rose further within the following month. The odds of a continued upward trend are .

MDNA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 29, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on MDNA as a result. In of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for MDNA entered a downward trend on September 22, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.045) is normal, around the industry mean (22.620). P/E Ratio (0.000) is within average values for comparable stocks, (131.496). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.087). Dividend Yield (0.000) settles around the average of (0.034) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (306.625).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. MDNA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.17B. The market cap for tickers in the group ranges from 402 to 407B. NVO holds the highest valuation in this group at 407B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -3%. For the same Industry, the average monthly price growth was 22%, and the average quarterly price growth was 38%. SLNO experienced the highest price growth at 494%, while SEEL experienced the biggest fall at -82%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 72%. For the same stocks of the Industry, the average monthly volume growth was 150% and the average quarterly volume growth was 108%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 87
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -26 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

MDNA is expected to report earnings to rise 67.45% to -4 cents per share on November 10

Medicenna Therapeutics Corp MDNA Stock Earnings Reports
Q3'23
Est.
$-0.05
Q2'23
Est.
$-0.03
Q1'23
Beat
by $0.02
Q4'22
Beat
by $0.01
Q3'22
Est.
$-0.01
The last earnings report on August 11 showed earnings per share of -2 cents, meeting the estimate of -2 cents. With 198.49K shares outstanding, the current market capitalization sits at 20.64M.
A.I. Advisor
published General Information

General Information

a clinical stage immuno-oncology company which engages in development and commercialization of selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Cytokines for the treatment of cancers

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
2 Bloor Street W.
Phone
+1 416 648-5555
Employees
16
Web
https://www.medicenna.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MAIA1.460.02
+1.39%
MAIA Biotechnology
BLTE31.24-0.03
-0.10%
Belite Bio
CHT35.80-0.46
-1.27%
CHUNGHWA TELECOM CO Ltd
INVE8.18-0.16
-1.92%
Identiv
LTHM17.34-0.80
-4.41%
Livent Corp

MDNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDNA has been loosely correlated with CRMD. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if MDNA jumps, then CRMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDNA
1D Price
Change %
MDNA100%
N/A
CRMD - MDNA
52%
Loosely correlated
-0.81%
NVAX - MDNA
32%
Poorly correlated
-2.74%
MESO - MDNA
27%
Poorly correlated
+0.82%
AXON - MDNA
26%
Poorly correlated
-1.88%
VRCA - MDNA
25%
Poorly correlated
+0.77%
More

Groups containing MDNA

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDNA
1D Price
Change %
MDNA100%
N/A
immuno-oncology
(undefined stocks)
19%
Poorly correlated
+3.46%
treatment
(undefined stocks)
14%
Poorly correlated
+2.37%
therapeutics
(undefined stocks)
8%
Poorly correlated
+8.06%